NCT05182697 - SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions

Autism Spectrum Disorder (ASD)

Interventions

DRUG

SCI-210

Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily

DRUG

Oral CBD oil

CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.

Trial Locations (1)

RECRUITING

Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel, Beersheba